Ｐｅｇｉｎｔｅｒｆｅｒｏｎ　ａｌｐｈａ－２ｂ＋ｒｉｂａｖｉｒｉｎ併用療法の効果判定におけるＣＯＢＡＳ　ＡｍｐｌｉＰｒｅ／ＣＯＢＡＳ　ＴａｑＭａｎ　ＨＣＶ　ｔｅｓｔの有用性

DOI Web Site Web Site 参考文献4件

書誌事項

タイトル別名
  • Clinical utility of COBAS AmpliPre/COBAS TaqMan HCV test for evaluating the efficacy of peginterferon plus ribavirin therapy
  • Peginterferon alpha 2b ribavirin ヘイヨウ リョウホウ ノ コウカ ハンテイ ニ オケル COBAS AmpliPre COBAS TaqMan HCV test ノ ユウヨウセイ

この論文をさがす

抄録

We evaluated the performance characteristics of Amplicor HCV v2.0 (Amplicor HCV) and COBAS AmpliPre/COBAS TaqMan HCV test (TaqMan HCV) for predicting sustained virological response (SVR) at 4, 8, and 12 weeks in patients treated with peginterferon plus ribavirin therapy. In genotype 1, the percentage of patients having SVR with undetectable HCV RNA by TaqMan HCV at 8 and 12 weeks is higher than that by Amplicor HCV (90.0% and 72.2% vs 84.6% and 60.0%). However, in genotype 2, there was no difference between Amplicor HCV and TaqMan HCV. We believe TaqMan HCV is useful for determining the duration of treatment with peginterferon plus ribavirin therapy, especially in genotype 1.<br>

収録刊行物

  • 肝臓

    肝臓 49 (4), 171-173, 2008

    一般社団法人　日本肝臓学会

参考文献 (4)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ